Zydus to present PBC and NASH clinical trial data of Saroglitazar Mg at the AASLD’s The Liver Meeting Digital Experience™ 2020
Zydus, a leading discovery based, global pharmaceutical company today announced that a Late-Breaker Oral Presentation and two Poster Presentations on Saroglitazar Mg has been accepted for presentation at The Liver Meeting® 2020, the Annual Meeting
Zydus, a leading discovery based, global pharmaceutical company today announced that a Late-Breaker Oral Presentation and two Poster Presentations on Saroglitazar Mg has been accepted for presentation at The Liver Meeting® 2020, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place virtually from November 13-16, 2020.
Saroglitazar Mg is in various stages of clinical trials to evaluate the safety, tolerability, and efficacy in patients with Primary Biliary Cholangitis (PBC) and Non Alcoholic Steato Hepatitis (NASH).
Speaking on the development, Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said, “We look forward to present the new data on Saroglitazar Mg at The Liver Meeting Digital Experience™, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Zydus is committed to developing novel therapies for patients living with liver diseases like PBC and NASH”.
Abstract Title: “RESULTS OF PHASE 2, PROSPECTIVE, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND EFFICACY OF SAROGLITAZAR MAGNESIUM IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (EPICS)”
Publication Number : LO12
Session Title : Late-breaking Oral Session 2
Presentation Type : Oral presentation
Session Date and Time: Monday, November 16, 2020, 2:00 PM
Abstract Title: “SAROGLITAZAR, A DUAL PPAR a/g AGONIST, RESOLVED STEATOHEPATITIS IN A RANDOMIZED DOUBLE BLINDED PLACEBO CONTROLLED PHASE 2 PROOF OF CONCEPT PILOT TRIAL”
Publication Number : 1695
Session Title : NAFLD and NASH: Therapeutics – Pharmacologic and Other
Presentation Type : Poster Presentation
Abstract Title: “SAROGLITAZAR ATTENUATES PRIMARY SCLEROSING CHOLANGITIS IN Mdr2−/− MICE MODEL: A COMPARISON WITH OBETICHOLIC ACID”
Publication Number : 1270
Session title : Human Cholestatic and Autoimmune Liver Diseases: PBC/PSC and Other Cholestatis Diseases; Autoimmune Liver Disease
Presentation Type : Poster Presentation
